WO2001034768A3 - 15 proteines secretees humaines - Google Patents

15 proteines secretees humaines Download PDF

Info

Publication number
WO2001034768A3
WO2001034768A3 PCT/US2000/030039 US0030039W WO0134768A3 WO 2001034768 A3 WO2001034768 A3 WO 2001034768A3 US 0030039 W US0030039 W US 0030039W WO 0134768 A3 WO0134768 A3 WO 0134768A3
Authority
WO
WIPO (PCT)
Prior art keywords
secreted proteins
human secreted
proteins
novel human
relates
Prior art date
Application number
PCT/US2000/030039
Other languages
English (en)
Other versions
WO2001034768A2 (fr
Inventor
Henrik S Olsen
George Komatsoulis
D Roxanne Duan
Reinhard Ebner
Steven M Ruben
Original Assignee
Human Genome Sciences Inc
Henrik S Olsen
George Komatsoulis
D Roxanne Duan
Reinhard Ebner
Steven M Ruben
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, Henrik S Olsen, George Komatsoulis, D Roxanne Duan, Reinhard Ebner, Steven M Ruben filed Critical Human Genome Sciences Inc
Priority to CA002389722A priority Critical patent/CA2389722A1/fr
Priority to EP00976752A priority patent/EP1230360A4/fr
Priority to JP2001537465A priority patent/JP2003513662A/ja
Priority to AU14487/01A priority patent/AU1448701A/en
Publication of WO2001034768A2 publication Critical patent/WO2001034768A2/fr
Publication of WO2001034768A3 publication Critical patent/WO2001034768A3/fr
Priority to US12/198,817 priority patent/US7968689B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

La présente invention concerne de nouvelles protéines sécrétées humaines et des acides nucléiques isolés contenant les régions codantes des gènes codant ces protéines. On décrit également des vecteurs, des cellules hôtes, des anticorps et des procédés de recombinaison utiles pour produire des protéines sécrétées humaines. L'invention concerne également des procédés de diagnostic et de thérapie utilisés pour diagnostiquer et traiter des maladies, des troubles et/ou des états liés à ces nouvelles protéines sécrétées humaines.
PCT/US2000/030039 1997-03-07 2000-11-01 15 proteines secretees humaines WO2001034768A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002389722A CA2389722A1 (fr) 1999-11-09 2000-11-01 15 proteines secretees humaines
EP00976752A EP1230360A4 (fr) 1999-11-09 2000-11-01 15 proteines secretees humaines
JP2001537465A JP2003513662A (ja) 1999-11-09 2000-11-01 １５個のヒト分泌タンパク質
AU14487/01A AU1448701A (en) 1999-11-09 2000-11-01 15 human secreted proteins
US12/198,817 US7968689B2 (en) 1997-03-07 2008-08-26 Antibodies to HSDEK49 polypeptides

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US16434499P 1999-11-09 1999-11-09
US60/164,344 1999-11-09
US19529600P 2000-04-07 2000-04-07
US60/195,296 2000-04-07
US22136700P 2000-07-27 2000-07-27
US60/221,367 2000-07-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/030654 Continuation-In-Part WO2001034629A1 (fr) 1997-03-07 2000-11-08 21 proteines humaines secretees

Related Child Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2000/030036 Continuation-In-Part WO2001034767A2 (fr) 1997-03-07 2000-11-01 22 proteines humaines secretees
US10/100,683 Continuation-In-Part US7368531B2 (en) 1997-03-07 2002-03-19 Human secreted proteins

Publications (2)

Publication Number Publication Date
WO2001034768A2 WO2001034768A2 (fr) 2001-05-17
WO2001034768A3 true WO2001034768A3 (fr) 2002-01-24

Family

ID=27389003

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/030039 WO2001034768A2 (fr) 1997-03-07 2000-11-01 15 proteines secretees humaines

Country Status (5)

Country Link
EP (1) EP1230360A4 (fr)
JP (1) JP2003513662A (fr)
AU (1) AU1448701A (fr)
CA (1) CA2389722A1 (fr)
WO (1) WO2001034768A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7267014B2 (ja) 2016-06-21 2023-05-01 アイオー バイオテック エーピーエス 癌ワクチンにおける使用のためのｐｄｌ１ペプチド

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001039722A2 (fr) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research Nouvelle molecule immunoregulatrice b7-h1,
EP1261736A4 (fr) * 2000-01-25 2004-12-29 Nuvelo Inc Methodes et materiaux associes a des polypeptides et des polynucleotides du type facteur-1 des preadipocytes (du type pref-1)
ATE385504T1 (de) 2000-06-06 2008-02-15 Bristol Myers Squibb Co Nukleinsäuren und polypeptide, die sich auf b7 beziehen und ihre verwendungen zur immunmodulierung
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
JP2005522986A (ja) * 2001-10-19 2005-08-04 ジェネンテック・インコーポレーテッド 炎症性腸疾患の診断と治療のための組成物と方法
AU2003245536A1 (en) * 2002-06-10 2003-12-22 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
US7892540B2 (en) 2004-10-06 2011-02-22 Mayo Foundation For Medical Education And Research B7-H1 and methods of diagnosis, prognosis, and treatment of cancer
JPWO2006101272A1 (ja) * 2005-03-25 2008-09-04 株式会社リバース・プロテオミクス研究所 創薬標的タンパク質及び標的遺伝子、並びにスクリーニング方法
BRPI0613361A2 (pt) 2005-07-01 2011-01-04 Medarex Inc anticorpo monoclonal humano isolado, composição, imunoconjugado, molécula biespecìfica, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, camundongo transgênico, método para modular uma resposta imune num indivìduo, método para inibir crescimento de células tumorais num indivìduo, método para tratar uma doença infecciosa num indivìduo, método para aumentar uma resposta imune a um antìgeno num indivìduo, método para tratar ou prevenir uma doença inflamatória num indivìduo e método para preparar o anticorpo anti-pd-l1
US20100136028A1 (en) 2006-11-07 2010-06-03 Sparrow Carl P Antagonists of pcsk9
WO2008118386A2 (fr) 2007-03-27 2008-10-02 Merck & Co., Inc. Procédé de détection de pcsk9 sécrétée, autogénérée
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
US8748115B2 (en) 2008-12-12 2014-06-10 Merck Sharp & Dohme Corp. PCSK9 immunoassay
AU2010313381A1 (en) 2009-10-30 2012-04-12 Merck Sharp & Dohme Corp. AX1 and AX189 PCSK9 antagonists and variants
JP2013509194A (ja) 2009-10-30 2013-03-14 メルク・シャープ・エンド・ドーム・コーポレイション Ａｘ２１３およびａｘ１３２ｐｃｓｋ９アンタゴニストおよびバリアント
CA2850245C (fr) * 2011-10-17 2020-04-28 Herlev Hospital Immunotherapie par pd-l1
CN110511278A (zh) 2012-05-07 2019-11-29 达特茅斯大学理事会 抗b7-h6抗体、融合蛋白及其使用方法
CN110352242A (zh) 2016-12-23 2019-10-18 哈佛大学的校长及成员们 Pcsk9的基因编辑

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003206A1 (fr) * 1996-07-24 1998-01-29 University Of Maryland Promoteur du gene de butyrophiline et utilisations de ce promoteur
WO1999013073A2 (fr) * 1997-09-08 1999-03-18 Rpr Gencell Asia/Pacific Inc. Systeme de vecteurs viraux capables d'exprimer un gene associe a l'apoptose

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2685599A (en) * 1998-02-18 1999-09-06 Genetics Institute Inc. Secreted proteins and polynucleotides encoding them
WO2001021631A2 (fr) * 1999-09-20 2001-03-29 Millennium Pharmaceuticals, Inc. Proteines secretees et leurs utilisations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003206A1 (fr) * 1996-07-24 1998-01-29 University Of Maryland Promoteur du gene de butyrophiline et utilisations de ce promoteur
WO1999013073A2 (fr) * 1997-09-08 1999-03-18 Rpr Gencell Asia/Pacific Inc. Systeme de vecteurs viraux capables d'exprimer un gene associe a l'apoptose

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1230360A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7267014B2 (ja) 2016-06-21 2023-05-01 アイオー バイオテック エーピーエス 癌ワクチンにおける使用のためのｐｄｌ１ペプチド

Also Published As

Publication number Publication date
JP2003513662A (ja) 2003-04-15
EP1230360A2 (fr) 2002-08-14
AU1448701A (en) 2001-06-06
CA2389722A1 (fr) 2001-05-17
WO2001034768A2 (fr) 2001-05-17
EP1230360A4 (fr) 2003-04-02

Similar Documents

Publication Publication Date Title
EP1053245A4 (fr) 45 proteines humaines secretees
WO1998039446A3 (fr) 70 proteines humaines secretees
WO1998039448A3 (fr) 186 nouvelles proteines secretees
WO1998040483A3 (fr) 28 proteines secretees par l'homme
WO1998031800A3 (fr) Proteines humaines
WO2001032910A3 (fr) 27 proteines humaines secretees
WO2001036432A3 (fr) 18 proteines secretees humaines
WO1998045712A3 (fr) 20 proteines humaines secretees
CY1111950T1 (el) 32 ανθρωπινες εκκρινομενες πρωτεϊνες
WO2001012776A3 (fr) 18 proteines secretees humaines
WO2001034768A3 (fr) 15 proteines secretees humaines
WO2000017222A8 (fr) 31 proteines humaines secretees
WO2000077026A8 (fr) 49 proteines secretees humaines
WO2000052136A3 (fr) Enzymes de glycosylation humaines
WO2000063230A3 (fr) 49 proteines secretees humaines
WO2000073323A3 (fr) Polynucléotides et polypeptides adam
WO2001062891A3 (fr) 207 proteines humaines secretees
EP1042342A4 (fr) 53 proteines secretees humaines
WO2000058339A3 (fr) 50 proteines humaines secretees
WO2001012775A8 (fr) 25 proteines secretees humaines
WO2000061624A8 (fr) 48 proteines secretees humaines
WO2000043495A3 (fr) Proteines humaines secretees (33)
WO2000061596A8 (fr) 50 proteines humaines secretees
WO2003052377A9 (fr) 41 proteines secretees humaines
WO2002099066A3 (fr) 20 proteines humaines secretees

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2389722

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 537465

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000976752

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000976752

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000976752

Country of ref document: EP